AMAROB Technologies

AMAROB Technologies is a French company specializing in the development of advanced microrobotic medical devices, particularly for laser surgical procedures, enhancing precision and safety in healthcare. Founded in 2020 by Sergio Lescano and Tristan Davaille, AMAROB Technologies is based in Besançon, France. The company focuses on creating innovative solutions for intracorporeal laser surgeries, utilizing advanced microrobotics. Sergio Lescano, the CEO, has a background in medical technology and entrepreneurship, although details on previous ventures are not provided.

AMAROB has secured funding through rounds, including a recent investment aimed at furthering its technological developments. AMAROB Technologies specializes in advanced microrobotic medical devices specifically designed for intracorporeal laser surgeries. Their flagship products include a miniature laser scalpel that utilizes a microrobot to precisely direct laser energy within the human body, and AgileGrip, a microforceps that facilitate the handling and exposure of tissues to the surgical laser. These innovative tools aim to enhance the safety and efficacy of surgical procedures by allowing for greater precision and reduced recovery times for patients.

Targeting hospitals and surgical centers, AMAROB’s products are primarily marketed within Europe and other regions that adopt advanced medical technology, providing valuable solutions to healthcare professionals conducting laser surgeries. AMAROB Technologies operates on a business-to-business (B2B) revenue model, generating revenue through direct sales of their specialized medical devices to healthcare institutions and surgical centers. The company engages in various transaction structures, including one-time purchases and potential long-term partnerships with hospitals for ongoing supply agreements. Pricing plans for their products reflect the advanced technology involved, determined based on the complexity of the devices and the terms negotiated with healthcare providers.

By focusing on high-value contracts with medical institutions, AMAROB aims to establish a robust revenue stream in the emerging market for robotic-assisted surgical devices. AMAROB Technologies plans to enhance its product line by developing additional microrobotic surgical tools aimed at further improving surgical outcomes. The company is also eyeing expansion into new markets, particularly targeting healthcare facilities in North America and Asia by 2025. Recent funding will be strategically allocated toward research and development of new products, as well as establishing partnerships with healthcare organizations in these new regions to facilitate market entry.